SAT0220 USE OF TOCILIZUMAB IN AORTITIS. A MULTICENTER STUDY OF 79 PATIENTS

Monica Calderón-Goercke, J. Loricera, D. Prieto-Peña, Vicente Aldasoro, Santos Castañeda, Ignacio Villa-Blanco, Alicia Humberia, Clara Moriano, Susana Romero-Yuste, J. Narváez, Catalina Gomez-Arango, Eva Perez-Pampin, Rafael Melero, Marcelino Revenga, Noelia Alvarez-Rivas, Francisca Sivera, María Álvarez del Burgo, Luisa Marena Rojas, Eva Galindez, Beatriz Arca, Roser Solans-Laqué, Carlos Vázquez, Pau Lluich, Eva Salgado-Pérez, Cristina Luna-Gomez, J Francisco. Toyos Sáenz de Miera, Nagore Fernández-Llanio, Antonio García, Carmen Larena, Natalia Palmou-Fontana, Vanesa Calvo-Río, Carmen González-Vela, Alfonso Corrales, María Varela-García, Elena Aurrecochea, Raquel Dos-Santos, José Luis Martín-Varillas, Sabela Fernández, J. Luis Hernández, Miguel A. González-Gay, Ricardo Blanco. *Rheumatology, Internal Medicine and Pathology Units, Santander, Navarra, Madrid, Torrelavega, León, Pontevedra, Barcelona, Mondragón, Santiago de Compostela, Vigo, Alicante, Lugo, Badalona, Palencia, Alcázar de San Juan, A Coruña, Granada, Bilbao, Avilés, Castellón, Salamanca, Zaragoza, Valencia, Menorca, Málaga, Ávila, Gijón, Ourense, Tenerife, Sevilla, Lérda, Spain*

Background: Aortitis can be idiopathic or associated with other conditions. It is frequently refractory to conventional immunosuppressive therapy. Tocilizumab (TCZ), an anti-IL-6 receptor antibody seems to be effective and safe.

Objectives: Our aim was to assess the efficacy and safety of TCZ at short and long follow-up in a series of patients with Aortitis.

Methods: Retrospective, multicenter study of 79 patients diagnosed of inflammatory aortitis based on imaging techniques (PET/CT, CT angiography and/or MR angiography).

Results: We study 79 patients (61 w/ 18 m). 59 (74.7%) cases were Aortitis secondary to Giant Cell Arteritis (GCA), while 20 (25.3%) were idiopathic. The mean age was 71±8.5 years vs 64.2±7.1 years, respectively (p=0.001). At time of disease diagnosis more than a half of patients (59.5%) presented as main symptom polymyalgia rheumatica (PMR). Aortitis was diagnosed with PET/CT (71 patients), angioRMN (12 patients) and angioCT (8 patients). Prior to TCZ treatment, 61 (77.2%) patients had received conventional immunosuppressive drugs, 59 (74.7%) of them received MTX. After 24 months of treatment with TCZ, more than 75% of patients reached a prolonged remission in both groups (p=0.527), with only 4% of relapses after the same follow-up period (p=1.000). 40 (50.6%) patients had a control image technique (PET/CT) throughout follow up. 4 (3 secondary to GCA and 1 idiopathic) patients reached a complete improvement in uptake after one year of treatment.

Conclusion: Our results show that idiopathic aortitis occurs in younger patients compared with aortitis secondary to GCA. TCZ proved to be effective in both pathologies, allowing clinical and analytical improvement, as well as a reduction of corticoid dose, without increasing the risk of relapse. However, the improvement in imaging techniques seems to be slower.

REFERENCE

- Loricera J, Blanco R, Castañeda S, Humberia A, Ortego-Centeno N, Narváez J, et al. Tocilizumab in refractory aortitis: study on 16 patients and literature review. *Clin Exp Rheumatol*. 2014; 32:79-89.

TABLE

	Idiopathic aortitis (n=20)	Aortitis secondary to GCA (n=59)	p
EFFICACY OF TCZ			
Prolonged remission, n (%)			
Month 6	5 (41.7)	23 (45.1)	0.830
Month 12	5 (45.5)	14 (41.2)	0.803
Month 24	3 (75)	18 (85.7)	0.527
Relapses, n (%)			
Month 1	2 (15.4)	1 (3.3)	0.213
Month 3	2 (16.7)	5 (10.4)	0.546
Month 6	1 (9.1)	8 (16.3)	0.544
Month 12	1 (9.1)	4 (11.8)	1.000
Month 24	0	1 (4.8)	1.000

Disclosure of Interests: Monica Calderón-Goercke: None declared, J. Loricera: None declared, D. Prieto-Peña: None declared, Vicente Aldasoro: None declared, Santos Castañeda Consultant for: Amgen, BMS, Pfizer, Lilly, MSD, Roche, Sanofi, UCB, Ignacio Villa-Blanco: None declared, Alicia Humberia: None declared, Clara Moriano: None declared, Susana Romero-Yuste: None declared, J. Narváez Consultant for: Bristol-Myers Squibb, Catalina Gomez-Arango: None declared, Eva Perez-Pampin: None declared, Rafael Melero: None declared, Marcelino Revenga: None declared, Noelia Alvarez-Rivas: None declared, Francisca Sivera: None declared, María Álvarez del Burgo: None declared, Luisa Marena Rojas: None declared, Eva Galindez: None declared, Beatriz Arca: None declared, Roser Solans-Laqué: None declared, Carlos Vázquez: None

declared, Pau Lluich: None declared, Eva Salgado-Pérez: None declared, Cristina Luna-Gomez: None declared, Francisco J. Toyos Sáenz de Miera: None declared, Nagore Fernández-Llanio: None declared, Antonio García: None declared, Carmen Larena: None declared, Natalia Palmou-Fontana: None declared, Vanesa Calvo-Río: None declared, Carmen González-Vela: None declared, Alfonso Corrales: None declared, María Varela-García: None declared, Elena Aurrecochea: None declared, Raquel Dos-Santos: None declared, José Luis Martín-Varillas: None declared, Sabela Fernández: None declared, J. Luis Hernández: None declared, Miguel A. González-Gay Grant/research support from: Prof. MA Gonzalez-Gay received grants/research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker's bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Ricardo Blanco Grant/research support from: Abbvie, MSD, and Roche, Consultant for: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen, Speakers bureau: Abbvie, Pfizer, Roche, Bristol-Myers, Janssen
DOI: 10.1136/annrheumdis-2019-eular.3571

SAT0221 OFF-LABEL USE OF BIOLOGICAL THERAPIES IN RELAPSING AND/OR REFRACTORY POLYARTERITIS NODOSA

Alice Canzian¹, Omer Karadag², Anne Contis³, Francois Maurier⁴, Silvia Sartorelli⁵, Laure Denis⁶, Sebastien Sanges⁷, Claire De Moreuil⁸, Cécile-Audrey Durel⁹, Stephane Durupt⁹, Marie Jachiet¹⁰, Diane Rouzaud¹⁰, Carlo Salvarani¹¹, Franco Schiavon¹², Lorenzo Dagna⁵, Fabrice Bonnet³, David Jayne¹³, Loïc Guillevin¹⁴, Benjamin Terrier¹⁵. ¹University of Parma, Parma, Italy; ²Hacettepe University, Ankara, Tunisia; ³CHU de Bordeaux, Bordeaux, France; ⁴Private Metz Hospital, Metz, France; ⁵IRCCS San Raffaele Hospital, Milan, Italy; ⁶CHU de Clermont-Ferrand, Clermont-Ferrand, France; ⁷CHU de Lille, Lille, France; ⁸CHU de Brest, Brest, France; ⁹CHU de Lyon, Lyon, France; ¹⁰Paris, Paris, France; ¹¹Università de Modena e Reggio Emilia, Reggio Emilia, Italy; ¹²University of Padova, Padova, Italy; ¹³University of Cambridge, Cambridge, United Kingdom; ¹⁴Université Paris Descartes, Paris, France; ¹⁵Paris Descartes University, Paris, France

Background: Polyarteritis nodosa (PAN) is a rare systemic necrotizing vasculitis of medium- and small-sized arteries, not associated with anti-neutrophil cytoplasmic antibodies (ANCA). Conventional treatments include glucocorticoids (GCs) for non-severe disease and a combination of GCs and immunosuppressive agents for severe disease. Nevertheless, some patients have refractory and/or relapsing disease.

Objectives: We examined the use of off-label biological therapy for relapsing/refractory PAN.

Methods: This retrospective European collaborative study included patients with PAN meeting ACR criteria and/or Chapel Hill Consensus Conference 2012 definitions. Treatment efficacy and safety are recorded. Remission was defined as the absence of vasculitis manifestations (BVAS = 0) with a prednisone dose ≤5 mg/day. Partial response was defined as a BVAS = 0 with a prednisone dose between 6 and 10 mg/day.

Results: Fifty-one patients (24 men, 27 women; median age 51 years) were included. Eighteen (35%) patients received TNF-alpha blockers, 16 (31%) received rituximab (RTX), 9 (18%) tocilizumab (TCZ), and 8 (16%) other biologics (including alemtuzumab in 3, anakinra in 2, interferon-alpha in 2 and abatacept in one). Previous treatments were: GCs in all cases, including methylprednisolone infusions (72%) and oral GCs (92%), cyclophosphamide (61%), azathioprine (53%), methotrexate (45%) and mycophenolate mofetil (47%). At inclusion, median BVAS was 5 (range 0-18), including 5 (2-12) in the TNF-alpha blockers group, 5 (2-12) in the RTX group and 4 (0-6) in the TCZ group.

After median follow-up of 34.4 months (IQR 21.5-59.5), remissions, partial responses and treatment failure, respectively, were noted in 41%, 6% and 53% for TNF-alpha blockers recipients, 25%, 12% and 63% for RTX recipients, and 57%, 0% and 43% for TCZ recipients. No remission was noted in patients treated with anakinra, alemtuzumab and abatacept. Median BVAS dropped to 3 at 6 months, 0 at 12 months and 0 at last follow-up in the TNF-alpha blockers group, to 3.5, 0 and 2 in the RTX group, respectively, and 0, 0 and 0 in the TCZ group. A GC-sparing effect seemed more important with TNF-alpha blockers and TCZ. Median GCs dose decreased from the baseline 15 mg/day to 10 at 6 months, 5 at 12 months and 5 at last follow-up in the TNF-alpha blockers group, from 15 mg/day to 10 at 6 months, 5 at 12 months and 10 at last follow-up in the RTX group, and from 15 mg/day to 7 at 6 months, 5 at 12 months and 5 at last follow-up in the TCZ group.

Four (22%) patients stopped TNF-alpha blockers because of allergic reaction in one and refractory disease in 3. Six (38%) stopped RTX because of refractory disease. Finally, 4 (44%) stopped TCZ because of adverse

events in 2 (testicular abscess and worsening renal failure) and refractory disease in 2.

Conclusion: The results of this study suggest that TNF-alpha blockers and TCZ may achieve higher rates of remission and GC-sparing in relapsing and/or refractory PAN than other biologics. Our data warrant further study to confirm or not these findings.

Disclosure of Interests: : Alice Canzian: None declared, Omer Karadag: None declared, Anne Contis: None declared, Francois Maurier: None declared, Silvia Sartorelli: None declared, Laure Denis: None declared, Sebastien Sanges: None declared, Claire De Moreuil: None declared, Cécile-Audrey Durel: None declared, Stephane Durupt: None declared, Marie Jachiet: None declared, Diane Rouzaud: None declared, Carlo Salvarani: None declared, Franco Schiavon: None declared, Lorenzo Dagna Consultant for: Prof Lorenzo Dagna received consultation honoraria from Abbvie, Amgen, Biogen, Bristol-Myers Squibb, Celltrion, Novartis, Pfizer, Sanofi-Genzyme, and SOBL., Fabrice Bonnet: None declared, David Jayne Grant/research support from: David Jayne has received research grants from Chemocentryx, GSK, Roche/Genentech and Sanofi-Genzyme. He has received consultancy fees from Astra-Zeneca, Boehringer-Ingelheim, Chemocentryx, Chugai, GSK, Infla-RX, Insmad and Takeda, Loïc Guillevin: None declared, Benjamin Terrier: None declared

DOI: 10.1136/annrheumdis-2019-eular.7185

SAT0222 COOPERATION OF T FOLLICULAR HELPER CELLS AND B CELLS IN TERTIARY LYMPHOID STRUCTURES IN TAKAYASU ARTERITIS

Anne-Claire Desbois¹, Anna Maciejewski-Duval², Paul Régnier², Valentin Quiniou², Cloé Comarmond², Hélène Vallet², Patrick Bruneval³, Pierre Fouret², Michele Rosenzweig², David Klatzmann², Fabien Koskas², Marlène Garrido², Guillaume Darrasse-Jèze², Patrice Cacoub², David Saadoun².
¹GHPS, Paris, France; ²Groupe Hospitalier La Pitié Salpêtrière, Paris, France; ³HEGP, Paris, France

Background: Takayasu's arteritis (TA) and giant cell arteritis (GCA), the two most common types of large vessel vasculitis (LVV), are characterized by an arterial inflammatory granulomatous infiltrate mainly located in the media and the adventitia. However, distinct histological features of the immune response are poorly known.

Objectives: To investigate distinct pathological mechanisms of the immune response in patients with GCA and TA.

Methods: We performed comparative immunohistochemistry analysis of aorta of GCA and TA patients. We performed microarray gene analysis of purified CD4+ T cells of TA and GCA patients. Reverse transcriptase PCR, flow cytometry analysis and cell culture were used to investigate T and B cells subpopulations in 54 patients with TA, 52 with GCA and 60 controls.

Results: We found higher proportion of tertiary lymphoid structures composed of CXCR5+, CD4+, PD-1+ and CD-20+ cells in inflammatory aortic lesions in TA as compared to GCA. We demonstrated increased proportion of aortic B cells in TA.

We next evaluated differentiation of circulating CD4+ T cells in both diseases. Among sixty-seven genes differentially expressed in CD4+ T cells of TA compared to GCA patients, we identified a specific "T follicular helper" (Tfh) signature in TA patients. We also found a specific Tfh 17 signature in TA patients. Flow cytometry analysis confirmed increased circulating Tfh, defined as CXCR5+ CD4+ T cells, in TA patients as compared to GCA and healthy donors (HD) [median of 15.4 (10;30.8)% versus 5.3 (1.4; 12.2)% and 9.7 (5.6; 12.5)% (p<0.0001 and p=0.0001)] in TA, GCA and HD, respectively. Among Tfh subpopulations, Tfh-17, CXCR5+ CCR6+ CXCR3- CD4+, cells were specifically increased in TA. Functionally, CXCR5+ CD4+ T cells of TA patients helped B cells to differentiate into memory cells, to proliferate and to secrete type G immunoglobulins.

We sequenced the TCR repertoire α/β in CD3+CD4+CXCR5- and CD3+CD4+CXCR5+ cells, in aortic and blood samples from 2 patients. In both patients, we identified oligoclonal profile of TCR repertoire only for aortic CXCR5+ cells, suggesting antigenic selection of CXCR5+ CD4+ T cells.

Conclusion: We provide evidence of the presence of tertiary lymphoid structures composed of Tfh and B cells in TA aorta. We identified a specific Tfh signature in circulating CD4+ T cells that distinguishes TA and GCA patients. The key cooperation of Tfh and B cells in TA and the oligoclonal repertoire of CXCR5+ CD4+ T cells strongly suggest the role of antigenic trigger.

Disclosure of Interests: : Anne-Claire DESBOIS Speakers bureau: SOBL en 2015, Anna Maciejewski-Duval: None declared, Paul Régnier: None declared, Valentin QUINIOU: None declared, Cloé Comarmond: None

declared, Hélène Vallet: None declared, Patrick Bruneval: None declared, Pierre Fouret: None declared, Michele Rosenzweig: None declared, David Klatzmann: None declared, Fabien Koskas: None declared, Marlène Garrido: None declared, Guillaume Darrasse-Jèze: None declared, Patrice cacoub Consultant for: d'Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Pfizer, Roche, Servier, and Vifor., Speakers bureau: d'Abbvie, Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Pfizer, Roche, Servier, and Vifor., David Saadoun Grant/research support from: Roche, Abbvie, Consultant for: Janssen, Celgene, Abbvie, Roche

DOI: 10.1136/annrheumdis-2019-eular.4852

SAT0223 FACTORS ASSOCIATED WITH DAMAGE PROGRESSION IN BEHÇET'S SYNDROME UVEITIS

Yilmaz Ozyazgan¹, Didar Ucar¹, Mustafa Erdogan², Yesim Ozguler², Gulen Hatemi², Sebahattin Yurdakul², Vedat Hamuryudan², Izzet Fresko², Melike Melikoglu², Emire Seyahi², Serdar Ugurlu², Hasan Yazici². ¹Istanbul University - Cerrahpasa Medical Faculty, Department of Ophthalmology, Istanbul, Turkey; ²Istanbul University - Cerrahpasa, Cerrahpasa Medical Faculty, Internal Medicine, Division of Rheumatology, Istanbul, Turkey

Background: Uveitis in Behçet's syndrome (BS) follows a recurrent disease course with inflammatory exacerbations causing damage in the uvea, retina and optic nerve even with treatment. Frequent attacks and posterior involvement are considered as predictors of poor visual outcome.

Objectives: The aim of this study is to delineate the predictors of damage in more detail using a standard screening method among a group of BS patients with long term regular follow-up.

Methods: Patients with uveitis who were registered in our multidisciplinary BS clinic between 1990 and 2008 were screened. Among these, 50 patients who were followed for at least 10 years, who were regularly seen in our clinic at least once in every 4 months, who did not have > Grade 2 damage at baseline, and who represented different levels of damage severity during the last visit (between Grade 0 and 5) were selected. The damage severity was graded according to a validated damage grading instrument (5=worst) specifically developed for BS uveitis (Ozyazgan et al. in preparation). One patient was later excluded because it was realized that he did not fulfill these criteria. A standard form was used for retrieving data on demographics, baseline and final visual acuities, number and localization (anterior/posterior/panuveitis) of attacks during follow-up, presence of retinal infiltration, retinal hemorrhage and hypopyon uveitis. Candidate factors for damage progression were compared between patients who had a progression in damage score and those who did not.

Results: 98 eyes of 49 patients (M:F 35:14, mean age at baseline 27±8 years, mean follow-up duration 20.9±5.5 years, mean number of visits 76.5±35.2) were evaluated. The mean visual acuity was 0.02±0.08 at baseline and 0.47±0.52 at the final visit. The mean number of attacks was 13.2±9.4. Damage grades at baseline were Grade 0 in 79, Grade 1 in 16 and Grade 2 in 3 eyes. Damage grades at final visit were Grade 0 in 15, Grade 1 in 21, Grade 2 in 32, Grade 3 in 12, Grade 4 in 10 and Grade 5 in 8 eyes. There was damage progression in 81/98 eyes at the final visit. Isolated anterior uveitis attacks were not associated with progression of damage (2.5±2.9 vs 2.8±5.5, p=0.7). Parameters that were significantly more frequent among patients with damage progression were: number of attacks (14.5±10.8 vs 23.3±12.3; p=0.008), number of posterior attacks (0.4±1.2 vs 6.5±4.9, p<0.001), number of panuveitis attacks (0.8±1.3 vs 6.6±5.0, p<0.001), number of attacks with severe vitreous opacity preventing examination of the retina (0 vs 3.2±3.8, p<0.001), retinal infiltration (0.2±0.4 vs 1.4±1.9, p<0.001) and retinal hemorrhages in the arcuate region (0.1±0.2 vs 0.7±1.4, p<0.001), and the number of hypopyon attacks (0.2±1.0 vs 0.9±1.3, p=0.019)

Conclusion: This study confirmed that the anterior uveitis attacks are not associated with progressive damage in BS, whereas posterior and panuveitis attacks, attacks causing severe vitreous opacity, retinal infiltrates and hemorrhage in the arcuate region and hypopyon attacks are important predictors of damage. Patients showing these features should be treated more aggressively.

REFERENCE

- [1] Ozyazgan, Yilmaz, et al. "Ocular involvement of Behçet's syndrome: a comprehensive review." *Clinical reviews in allergy & immunology* 49.3 (2015): 298-306.